Introduction {#sec1-1}
============

Liver cirrhosis is the 10th most common cause of death in Western world.^[@ref1]^ Among the complications of the end-stage liver disease (ESLD), infection represents the leading cause of acute decompensation^[@ref2],[@ref3]^ and is associated with a high mortality ranging from 12 to 52%.^[@ref4],[@ref5]^

Despite these patients are particularly prone to develop bacterial and fungal infections, ^[@ref6]^ the cirrhosis of the liver is not commonly considered a major immunodepressive condition. However, patients with ESLD exhibit an important impairment of immune system. This condition, called cirrhosis- associated immune dysfunction (CAID) summarizes both local and systemic immune system alterations in liver cirrhosis that play a pivotal role in determining both the high incidence of infections and the ominous infections related mortality in this patient population.^[@ref7],[@ref8]^ Overall mortality of infected cirrhotic patients in around 30% at 1 month and more than 50% at 12 months.^[@ref8]^ The high mortality rate of infections in cirrhotic patients is related not only to the direct effects of infections but, above all, to their pivotal role in triggering the condition of acute-on-chronic liver failure (ACLF). For this reason, infection is considered an important prognostic marker in patients with ESLD.

Another concerning feature of infections in cirrhotic patients is the growing prevalence of multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens, which are associated with higher mortality, increased length of in-hospital stay and higher healthcare related costs if compared with infection caused by susceptible strains.^[@ref9]^ In addition to these clinical features, the threat of MDR/XDR pathogens relies on their ability to rapidly spread to patients in absence of contact precautions. As a consequence, an important transmission of MDR gram-negative bacilli between patients is observed during outbreaks.^[@ref12]^

In this setting a multifaceted approach is needed to face all the management challenges offered by patients with ESLD with infection. This include the knowledge of contemporary epidemiology, the development of prognostic tools and testing of novel therapeutic strategies.

Epidemiology {#sec1-2}
============

In light of the emerging threat of multidrug- resistant organisms (MDRO), mainly related the ominous spread of extendedspectrum beta-lactamase producing (ESBL) and carbapenem-resistant Enterobac - teriaceae (CRE) and carbapenem resistant non-fermenting bacilli in the last decade, an increasing number of epidemiological studies were recently published. To better understand the evolution of epidemiology of bacterial and fungal infections in this setting the most representative studies are summarized in the [Table 1](#table001){ref-type="table"}.^[@ref13]^

The wide variability in term of site of infection and causative pathogens is mainly related to several factors. First, with exception of spontaneous bacterial peritonitis (SBP), there is no agreement for most of infection definitions and most studies did not adopted the widely agreed criteria for infection diagnosis used in non-cirrhotic population. Second, the epidemiology of infection is currently under constant evolution and may vary between centers. Third, similarly to the previous point, different study site may be characterized by different level of commitment in the management of cirrhotic patients. Thus, tertiary sites with dedicated liver unit and access to a transplantation program may exhibit a population with more advanced stage of liver disease if compared with urban hospitals. Despite inhomogeneity, these studies clearly show that the rate of MDRO has increased dramatically and the improvement of the management of liver cirrhosis may have changed also the characteristics of infection site. In fact, in the studies published in the 90' and in the first years of the 21th Century the diagnosis of SBP was prevalent (24-56% of cases). Conversely latter studies report a lower prevalence of SBP (8-18%, excluding one paper that included bacterial ascites in the definition of SBP and reported 42% of such infections) and higher rate of bloodstream infection (6-28%) and pneumonia (7-38%).

Few studies reported to date differences in the kind of infection and in the causative pathogens in patients with alcoholic liver disease (ALD) and patients with other causes of liver cirrhosis. Previous studies on bloodstream infections (BSI) including mainly patients with alcoholic cirrhosis report a higher prevalence of gram-positive cocci (GPC) among the different etiologies of BSI. However most of these studies are old or characterized by a single-center design.^[@ref22],[@ref23]^ In addition, infection in alcoholic cirrhosis seems to be characterized by higher frequency of ACLF, however conflicting results on the outcome are reported. ^[@ref3],[@ref24]^

Risk factors for multidrug-resistant Pathogens {#sec1-3}
==============================================

To date few studies evaluated risk factors for MDRO in the setting of cirrhosis ([Table 2](#table002){ref-type="table"}).^[@ref4],[@ref9],[@ref25]^

Most of the reported studies focused on SBP whereas only 2 studies included all various sources of infection. The most reported risk factors for MDR were antibiotic exposure (antibiotic prophylaxis, use of third generation cephalosporines, fluoroquinolones or beta-lactams) and exposure to healthcare environment (*i.e*. hospital acquired or healthcare associated infections, previous hospital admission).

Prognosis {#sec1-4}
=========

As mentioned before the high mortality rate of infections in cirrhotic patients is related not only to the direct effects of infections but, above all, to their pivotal role in triggering the condition of acute-onchronic liver failure (ACLF). In a prospective multicenter study (CANONIC study), bacterial infection was found to be the precipitating event of ACLF in 32% of cases.^[@ref30]^ A further analysis of the CANONIC study revealed that BSI, pneumonia and SBP are more likely to be associated with ACLF. In addition, in patients with grade I and II ACLF, the presence of bacterial or fungal infection was associated with a worse outcome. ^[@ref31]^ Similarly, in a single-center study enrolling patients with ACLF, bacterial infection was a predictor of 30-day mortality. ^[@ref32]^ Despite these findings, a better understanding of the interaction between bacterial infection and ACLF is needed. In fact, the specific role of different kind of infections in determining ACLF and its risk factors are not clearly established.

Infection is considered an important prognostic marker in patients with ESLD. In a large multicenter cohort of patients with biopsy-proven compensated viral cirrhosis, the occurrence of a bacterial infection impaired survival both in HCV-infected (5-year survival: 60.2% *vs* 90.4%, P\<0.001) and HBV-infected patients (5-year survival: 69.2% *vs* 97.6%, P\<0.001), representing the third cause of death (14.1%) after liver failure and liver cancer. Similarly, in a singlecenter study enrolling 501 patients, bacterial infection was independently associated to mortality. The authors concluded that bacterial infection represents a different stage of the disease, which affect survival, even after recovery form an infectious episode.^[@ref13]^

Antimicrobial pharmacokinetic/pharmacodynamic issues in liver cirrhosis {#sec1-5}
=======================================================================

Ensuring a prompt and appropriate empirical antimicrobial treatment for infections in liver cirrhosis is essential in liver cirrhosis.^[@ref33],[@ref34]^

The concept of appropriateness for empirical and targeted antimicrobial treatment relies on a right antimicrobial coverage associated with an appropriate exposure consistent with the drugs' pharmacokineticpharmacodynamic (PK/PD) features. PK variability is a major contributor to therapeutic failure: therefore to guarantee a correct exposure to antibiotics, timely administration of the right dose at the right schedule, according to the pathophysiological and immunological status of the patient, is required.^[@ref35]^

Patient with liver cirrhosis have several unique pathophysiological characteristics that can alter the PK/PD behavior and the *in vivo* activity of antimicrobial agents. These characteristics include: i) hypoalbuminemia and reduction binding to proteins; ii) altered distribution; iii) altered clearance of the antimicrobial.^[@ref36]^

The reduction of antimicrobial protein binding is a consequence of decreased albumin production and accumulation of antibiotic binding inhibitors (such as bilirubin or α-acid glycoprotein) in patients with liver cirrhosis.^[@ref37]^ Depending on the degree of antibiotic protein binding, patients with liver cirrhosis may have, both in plasma and tissues, a higher fraction of unbound drug. This is the microbiologically active drug, but also the fraction that is cleared more rapidly through renal or hepatic pathways. Hence, patients with hypoalbuminemia have a higher proportion of drug *escaping* from the bloodstream and distributing into tissues, translating to increased distribution volume (Vd) and reduced or sometimes sub-therapeutic bloodstream concentrations required to treat severe infection.^[@ref37],[@ref38]^

In patients with advanced liver cirrhosis, splanchnic congestion and fluid retention due to hypoalbuminemia and reduced renal blood flow can further increase the Vd for relatively hydrophilic antibiotics, such as beta-lactams, aminoglycosides, and vancomycin. As a result, most of the patients with ACLF presents with edema, ascites and third space expansion resulting in inadequate blood levels of these antibiotics.^[@ref38],[@ref39]^ Therefore, larger loading and daily doses and are often required for hydrophilic antibiotics to achieve therapeutic blood levels.

On the other hand, increased Vd may also prolong the drug elimination irrespective of the clearance rates.^[@ref37]^ In some patients with liver cirrhosis, antibiotics halflife is increased, paradoxically causing drug accumulation and potential for toxicity.^[@ref40]^

Finally, the PK of antibiotics can be affected by liver-disease related changes in renal function that are very common in this population. Renal failure in liver cirrhosis is mainly due to a reduced renal perfusion secondary to a vasodilatation in the splanchnic circulation without a compensation of cardiac output.^[@ref41]^ Although clearance of creatinine is widely accepted as a viable method for renal function assessment, several studies demonstrate that measured creatinine clearance from timed urine collection may overestimate the glomerular filtration rate in LC even in patients without hepatorenal syndrome.^[@ref42]^

Unfortunately, antibiotic PK/PD is rarely studied in patients with liver dysfunction, especially in patients with advanced cirrhosis and ascites (*i.e*. Child-Pugh Class C). This kind of patients are commonly excluded form phase 1, phase 2 and phase 3 studies. Consequently, there is currently little or no scientific basis for antibiotic doses currently administered to treat life-threatening infections in patients with advanced cirrhosis. Given the unpredictable drug exposure, therapeutic drug monitoring (TDM) might play a pivotal role for individualizing doses, both in lowering exposure-dependent toxicity and in ensuring an optimal drug exposure, especially for the treatment of serious infections or MDR pathogens.

Beta-lactams are commonly used and represent the first-line therapy of most infection in patients with liver cirrhosis.^[@ref43]^ Beta-lactams are time-depending drugs which ensure the best effectiveness with a prolonged time of exposure above the pathogen minimal inhibitory concentration (T\>MIC).^[@ref44]^ Previous studies in general population indicate that continuous or extended infusion of beta-lactams is associated to better drug exposure and higher T\>MIC and consequently better outcome for severe infection.^[@ref45]^

According with the aforementioned pathophysiological characteristics, the cirrhotic patient seems an important setting to test continuous infusion of beta-lactams for treating severe infections.

Conclusions {#sec1-6}
===========

Bacterial and fungal infection is common in the natural history of liver cirrhosis and seems to have an impact on prognosis. Several aspects of infections deserve further investigation, such as the interaction between infection and ACLF. Additional studies are needed to assess novel therapeutic strategies like continuous infusion of beta-lactams on the outcome of infection in this setting.

###### 

Summary of epidemiological studies on patients with liver cirrhosis. Only studies including all different source of infection are reported.

  Author/year/geographic area (ref)        Population                Most representative source of infection, %   Etiology (prevalence of MDRO), %                                                                                       
  ---------------------------------------- ------------------------- -------------------------------------------- ---------------------------------- ---- ---- -------------------------------- ---------------------------------------- ----
  Studies published in the 90'                                                                                                                                                                                                           
  Caly/1993/Brazil (14)                    All cirrhotics            31                                           25                                 25   NR   72 (NR)                          28                                       NR
  Toledo/1994/Spain (15)                   All cirrhotics            44                                           26                                 10   5    65 (61 *E.coli*)                 39                                       NR
  Studies published from 2000 to 2015                                                                                                                                                                                                    
  Borzio/2001/Italy (16)                   All cirrhotics            23                                           41                                 17   21   46                               49                                       4
  Rosa/2000/Brazil (17)                    All cirrhotics            54                                           7                                  18   NR   NR                               NR                                       NR
  Fernandez/2002/Spain (18)                All cirrhotics            24                                           19                                 13   5    45                               47                                       NR
  Fernandez/2012/Spain (4)/first series    All cirrhotics            56                                           43                                 20   13   44 (MRSA 3% of all infections)   46 (ESBL 9% of all infections)           NR
  Fernandez/2012/Spain (4)/second series   All cirrhotics            20                                           25                                 13   13   MRSA 7% of all infections        ESBL 7% of all infections                NR
  Studies published from 2015 to 2017                                                                                                                                                                                                    
  Merli/2015/Italy (9)                     All cirrhotics            8                                            61                                 12   6    47                               47                                       NR
  Park/2015/Korea (19)                     Alcoholic liver disease   9                                            4                                  38   4    35 (MRSA 86%)                    63 (ESBL in 42% of Enterobacteriaceae)   2
  Dionigi/2017/England (13)                All cirrhotics            42                                           19                                 9    28   58 (MRSA 18%)                    41 (ESBL 20% of GNB)                     NR
  Salerno/2017/ (21) Italy and England     All cirrhotics            18                                           43                                 7    17   58 (MRSA 51%)                    47 (44% ESBL production, 9% CR-GNB       3
  Piano/2017/Italy (21)                    All cirrhotic             33                                           23                                 14   13   46                               47                                       7

MDRO multidrug-resistant organisms; SBP spontaneous bacterial peritonitis; UTI urinary tract infection; LRTI low respiratory tract infection; BSI bloodstream infection; MRSA methicillin resistant *Staphylococcus aureus*; ESBL extended-spectrum beta-lactamase; CRE carbapenem-resistant Enterobacteriaceae; NR not reported

###### 

Risk factors for multidrug-resistant pathogens in patients with liver cirrhosis and infection.

  Author/Year/Geographic Area (Ref)        Kind of infections         Prevalence and kind of MDRO                                Risk factors
  ---------------------------------------- -------------------------- ---------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  Merli/2015/Italy (9)                     All bacterial infections   51%                                                        Antibiotic prophylaxis; HA or HCA infections
  Kim/2013/Korea (25)                      Community-onset SBP        32% of FQ resistant E.coli                                 FQ use (30dd); Previous SBP episode; Third-generation cephalosporin resistance
  Fernandez/2012/Spain (4)/ first series   All bacterial infections                                                              Nosocomial origin of infection; Long-term norfloxacinprophylaxis; Recent infection by multi-resistant bacteria; Recent use of b-lactams
  Chaulk/2013/Canada (26)                  SBP                        19% third-generation cephalosporin resistance              Nosocomial acquisition of infection
  Song/2009/Korea (27)                     SBP                        7% ESBL-Enterobacteriaceae                                 Nosocomial acquisition; Previous SBP episode
  Alexopolu/2012/Greece (28)               SBP                        24%                                                        MELD score; HCA; Quinolone prophylaxis
  Ariza/2012/Spain (29)                    HA and HCA SBP             42% third generation cephalosporine resistance of HA SBP   Diabetes mellitus; Upper GI bleeding; Hospital acquired; Previous 3^rd^ Gen Cephalosporine use

MDRO, multidrug-resistant organisms; HA hospital associated; HCA healthcare associated; FQ fluoroquinolone; SBP spontaneous bacterial peritonitis; ESBL extended-spectrum beta-lactamase; MELD Model for End- Stage Liver Disease; GI gastrointestinal
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